

GSK2636771

## Chemical Properties


CAS No. : 1372540-25-4

Formula: C<sub>22</sub>H<sub>22</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>

Molecular Weight: 433.42

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	GSK2636771, an effective, specific, orally bioavailable, PI3K $\beta$ inhibitor, has been used in cancer, lymphoma, solid neoplasm, recurrent solid neoplasm, and advanced malignant neoplasm.
Targets(IC50)	PI3K
In vitro	In mice, GSK-2636771 (at a dosage of 100 mg/kg) does not elevate glucose/insulin levels. In xenograft tumor models, GSK-2636771 decreases the levels of phosphorylated protein kinase Akt (Ser473).
In vivo	In PTEN-deficient cell lines, GSK-2636771 exhibits specific inhibitory activity, with EC50 values of 36 nM in human prostate cancer PC-3 and 72 nM in breast cancer HCC70.
Cell Research	Cells are plated in 96-well microtiter plates at densities ranging from 1,500 to 15,000 cells/well, optimized for untreated control cells to be 80-90% confluent at the endpoint of the experiment. After 24 h, cells are treated with serial dilutions (100pM to 10 $\mu$ M) of GSK2636771. Cell viability is assessed after 72 h of treatment by incubation with CellTiter Blue for 1.5 h. The drug concentration requires for survival of 50% of cells relative to untreated cells (surviving fraction 50, SF50) is determined using GraphPad Prism version 5.0d. Cell lines that fails to achieve the SF50 to a given drug are nominally assigned as the highest concentration screened (i.e. 10 $\mu$ M). At least three independent experiments in triplicate per cell line targeted drug are performed. Association between a mutation and response to a targeted agent is determined using a Fisher's exact test (GraphPad Prism), and a two-tailed P value <0.05 is considered statistically significant. (Only for Reference)

## Solubility Information

Solubility	H <sub>2</sub> O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: < 1 mg/mL (insoluble or slightly soluble), DMSO: 13.75 mg/mL (31.72 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.3072 mL	11.5362 mL	23.0723 mL
5 mM	0.4614 mL	2.3072 mL	4.6145 mL
10 mM	0.2307 mL	1.1536 mL	2.3072 mL
50 mM	0.0461 mL	0.2307 mL	0.4614 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

#### Reference

Macauley D, et al. *Drugs Fut*, 2012, 37(6), 451.

Weigelt B, et al. *Clin Cancer Res*. 2013, 19(13), 3533-3544.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481